Meta-Analysis of Clinical Efficacy and Safety of Ligustrazine in the Treatment of Idiopathic Pulmonary Fibrosis.

Objective: To systematically review the efficacy and safety of Ligustrazine in the treatment of idiopathic pulmonary fibrosis (IPF).

Methods: The electronic literature databases (PubMed, EMbase, CNKI, WanFang database, and VIP) were retrieved through a computer to find out the randomized controlled trials (RCT) of Ligustrazine in the treatment of IPF according to the inclusion/exclusion criteria screening test. Cochrane's bias risk table was also used to evaluate the quality of the study and to extract effective data. RevMan 5.3 was used for statistical analysis.

Results: A total of 7 RCTs (a total of 366 patients, including 196 in experimental and 170 in control group). Compared with the control group, Ligustrazine could improve the clinical symptoms ([OR] = 2.20, 95% CI [1.40, 3.46], =0.0006), lung function (VC % [MD] = 3.92, 95% CI [0.68, 7.17], =0.02), (TLC% [MD] = 4.94, 95% CI [0.37, 9.52], =0.03), the pulmonary diffusion function (DLCO % [MD] = 9.12, 95% CI [5.70, 12.55], < 0.00001), and arterial blood gas analysis (PaO [MD] = 7.11, 95% CI [1.96, 12.25], =0.007) (PaCO [MD] = -2.42, 95% CI [-4.36, -0.49], =0.01) of IPF patients, respectively. However, FEV/FVC % ([MD] = 9.37, 95% CI [-1.23, 19.97], =0.08) and adverse reactions ([MD] = 0.35, 95% CI [0.02, 5.36], =0.45) were not significantly improved.

Conclusion: Ligustrazine has certain clinical efficacy in the treatment of IPF, but the safety of applying it and the adverse reactions need to be further analyzed and determined. It can be considered as a new alternative and complementary medicine to be promoted and recommended for use in medical units in various countries in the world and it solved the difficult problem of conventional drug treatment of IPF; therefore, more research strength can be put in the treatment of the pathological mechanism of IPF for further exploration. The study was registered under registration number CRD42020193626.